AGPAT2

Across TCGA pan-cancer cohorts, AGPAT2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of AGPAT2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where AGPAT2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types AGPAT2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

COAD, LSCC, and HNSC are the cancer types where AGPAT2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AGPAT2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+0.263	<.001	9	view →
LSCC	Female	II,III,IV	−0.622	<.001	8	view →
HNSC	Female	All	+0.540	.046	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

AGPAT2–COAD

Open the COAD breakdown →